Aida Files 10Q

SANTA MONICA, Calif., Nov. 15  /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA)  today announced that it has filed its form 10Q for the period ended September 30, 2007.  Net revenues totaled $7,373,770 for the quarter ended 9/20/07, an increase of 5% over the same period in 2006.  Gross profit decreased by 2.66% due to an increase in Costs of Goods Sold.  Most notably, sales from Aida's transfusion and injection forms of etimicin sulfate increased markedly.  Gross profit margins for Aida remained very strong, decreasing slightly from 55.81% to 51.75%.

Aida management expects the decrease in profits to be temporary.  The Chinese pharmaceutical industry is in a state of transition due to policy changes by China's State Food and Drug Administration (SFDA).  The new medicine tender system for hospitals in some areas in 2007 requires hospitals to purchase medicines and drugs directly from pharmaceutical manufacturers rather than distributors, which resulted in sales returns from some distributors. Aida has proactively and rapidly revised its distribution channels and is ready to compensate for the national policy changes.  Aida also expects a strong showing from the new drugs in its pipeline that are coming to market in the coming quarters.  Aida expects that these drugs will ease Aida's reliance on etimicin sulfate as a revenue generator and lessen the fluctuation in the Company's performance.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices.

Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation

                        AIDA PHARMACEUTICALS, INC.
             (FORMERLY BAS CONSULTING, INC.) AND SUBSIDIARIES
                    CONDENSED CONSOLIDATED STATEMENTS
                    OF INCOME AND COMPREHENSIVE INCOME
                               (UNAUDITED)


                            FOR THE THREE MONTHS     FOR THE NINE MONTHS
                                   ENDED                    ENDED
                               SEPTEMBER  30,            SEPTEMBER 30,
                            2007          2006        2007         2006

  REVENUES, (NET)        $7,373,770    $7,023,891  $18,687,283  $19,659,235

  COST OF GOODS SOLD     (3,557,685)   (3,103,516)  (9,740,952)  (9,679,567)

  GROSS PROFIT            3,816,085     3,920,375    8,946,331    9,979,668

  Selling and
   distribution           1,387,818     1,175,000    3,515,776    4,728,989

  General and
   administrative           991,216     1,306,226    3,006,799    2,896,205

  Research and
   development               74,514        45,323      238,159       45,111

  INCOME FROM
   OPERATIONS             1,362,537     1,393,826    2,185,597    2,309,363

  OTHER INCOME
   (EXPENSES)

     Interest expense,
      net                  (465,282)     (459,511)  (1,180,813)  (1,114,105)

     Government grants       46,131       551,420       95,998    1,097,724

     (Loss) gain on
      sales of
      investment            (10,457)           --      (10,457)      12,490

     Gain on sale of
      marketable
      securities                 --            --      120,356           --

     Other income
      (loss), net            (3,478)      (77,358)    (122,876)    (120,734)

  INCOME BEFORE INCOME
   TAXES                    929,451     1,408,377    1,087,805    2,184,738

  INCOME TAXES             (153,182)     (217,720)    (191,349)    (445,047)

  INCOME BEFORE
   MINORITY INTERESTS       776,269     1,190,657      896,456    1,739,691

  MINORITY INTERESTS       (257,208)     (271,372)    (563,068)    (413,018)

  NET INCOME                519,061       919,285      333,388    1,326,673

  OTHER COMPREHENSIVE
   INCOME
  Foreign currency
   translation gain          30,098        73,643      492,663      160,785

  OTHER COMPREHENSIVE
   INCOME BEFORE INCOME
   TAXES                     30,098        73,643      492,663      160,785

  INCOME TAXES RELATED
   TO OTHER
   COMPREHENSIVE
   INCOME                    (7,946)      (24,302)    (130,063)     (54,012)

  OTHER COMPREHENSIVE
   INCOME, NET OF
   INCOME TAXES              22,152        49,341      362,600      106,773

  COMPREHENSIVE INCOME     $541,213      $968,626    $ 695,988   $1,433,446

  WEIGHTED AVERAGE
   SHARES OUTSTANDING
   BASIC AND DILUTED     27,000,000    25,000,000   27,000,000   25,000,000

  NET INCOME PER COMMON
   SHARE, BASIC AND
   DILUTED                    $0.02         $0.04        $0.01        $0.05


DATASOURCE: Aida Pharmaceuticals, Inc.



CONTACT:  Ashley Hull of ProPublic Media, LLC, [phone],

, for Aida Pharmaceuticals, Inc.

Copyright